Evaluation of the Pathobiology of CALR-mutated MPN Cells
Sponsor: Atrium Health Levine Cancer Institute
This observational or N/A phase trial investigates Myeloproliferative Neoplasm and is currently actively recruiting participants. Atrium Health Levine Cancer Institute leads this study, which shows 8 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Recruiting
-
Aug 2025 — Feb 2026 [monthly]
Recruiting
-
Feb 2025 — Aug 2025 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Dec 2024 — Feb 2025 [monthly]
Not Yet Recruiting
-
Oct 2024 — Dec 2024 [monthly]
Not Yet Recruiting
▶ Show 3 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Atrium Health Levine Cancer Institute
- Brookdale University Hospital Medical Center
- Wake Forest University Health Sciences
For direct contact, visit the study record on ClinicalTrials.gov .